Table 2.
Characteristics of cases and controls in the common phase II set and the PLCO phase III data.
| “Common” Phase II Data
|
Phase III Data
|
||||
|---|---|---|---|---|---|
| Cases N=160 | BD controls N=160 | GP controls N=480 | Cases N=118 | Controls N=474 | |
| Center | |||||
| FCCC | 41 (25.6) | 11 (6.7) | 121 (25.2) | -- | -- |
| FHCRC | 39 (24.4) | 39 (24.4) | 118 (24.6) | -- | -- |
| Partners | 40 (25.0) | 110 (68.8) | 121 (25.2) | -- | -- |
| MDACC | 40 (25.0) | 0 (0.0) | 120 (25.0) | -- | -- |
| Age | |||||
| 30-55 | 68 (42.5) | 73 (45.6) | 209 (44.8) | 0 (0.0) | 0 (0.0) |
| 55-59 | 31 (19.4) | 26 (16.2) | 88 (18.9) | 14 (11.9) | 60 (12.7) |
| 60-64 | 21 (13.1) | 28 (17.5) | 73 (15.7) | 37 (31.4) | 146 (30.8) |
| ≥65 | 40 (25.0) | 33 (20.6) | 96 (20.6) | 67 (56.8) | 268 (56.5) |
| Menopausal status | |||||
| Pre | 44 (30.6) | 43 (31.2) | 139 (36.7) | 0 (0.0) | 0 (0.0) |
| Post | 100 (69.4) | 95 (68.8) | 240 (63.3) | 118 (100.0) | 474 (100.0) |
| Race | |||||
| White | 122 (76.2) | 127 (79.4) | 338 (73.2) | 106 (89.8) | 431 (90.9) |
| Non-white | 38 (23.8) | 33 (20.6) | 124 (26.8) | 12 (10.2) | 43 (9.1) |
| BMI | |||||
| <22 | 21 (18.3) | 24 (18.3) | 41 (20.5) | 22 (18.6) | 66 (14.0) |
| 22-24.9 | 32 (27.8) | 38 (29.0) | 59 (29.5) | 31 (26.3) | 113 (24.0) |
| 25-29.9 | 23 (20.0) | 38 (29.0) | 53 (26.5) | 37 (31.4) | 178 (37.9) |
| ≥30 | 39 (33.9) | 31 (23.7) | 47 (23.5) | 28 (23.7) | 113 (24.1) |
| Smoking | |||||
| Never | 68 (59.6) | 73 (55.7) | 176 (55.5) | 64 (54.2) | 291 (61.4) |
| Former | 29 (25.4) | 40 (30.5) | 112 (35.3) | 46 (39.0) | 149 (31.4) |
| Current | 17 (14.9) | 18 (13.7) | 29 (9.2) | 8 (6.8) | 34 (7.2) |
| Case characteristics | |||||
| Histology | |||||
| Serous | 88 (55.0) | -- | -- | 68 (57.6) | -- |
| Mucinous | 14 (8.8) | -- | -- | 2 (1.7) | -- |
| Endometrioid | 17 (10.6) | -- | -- | 14 (11.9) | -- |
| Clear cell | 9 (5.6) | -- | -- | 4 (3.4) | -- |
| Squamous cell | 1 (0.6) | -- | -- | 0 (0.0) | -- |
| Mixed epithelial | 23 (14.4) | -- | -- | 0 (0.0) | -- |
| Undifferentiated | 1 (0.6) | -- | -- | 2 (1.7) | -- |
| Other | 5 (3.1) | -- | -- | 3 (2.5) | -- |
| Adenocarcinoma NOS | 0 (0.0) | -- | -- | 22 (18.6) | -- |
| Unknown | 2 (1.2) | -- | -- | 0 (0.0) | -- |
| Granulosa cell | 0 (0.0) | -- | -- | 3 (2.5) | -- |
| Grade | |||||
| 0 | 33 (20.6) | -- | -- | -- | -- |
| 1 | 11 (6.9) | -- | -- | 7 (5.9) | -- |
| 2 | 11 (6.9) | -- | -- | 22 (18.6) | -- |
| 3-4 | 85 (53.1) | -- | -- | 66 (55.9) | -- |
| Unknown | 20 (12.5) | -- | -- | 23 (19.5) | -- |
| Stage | |||||
| Early | 74 (46.2) | -- | -- | 32 (27.1) | -- |
| Late | 83 (51.9) | -- | -- | 84 (71.2) | -- |
| Unknown | 3 (1.9) | -- | -- | 2 (1.7) | -- |